

1

2

3

4 Development and Evaluation of AccuPower® COVID-19 Multiplex

5 Real-Time RT-PCR Kit and AccuPower® SARS-CoV-2 Multiplex

6 Real-Time RT-PCR Kit for SARS-CoV-2 Detection in Sputum,

7 NPS/OPS, Saliva and Pooled Samples.

8

9 Suh In Bum¹, Jaegyun Lim², Hyo Seon Kim³, Guil Rhim⁴, Kim Heebum¹, Kim Hana¹, Lee
10 Sae-Mi¹, Park Hyun-sang¹, Song Hyun Ju¹, Hong MyungKook¹, Shin Gyung Sook¹, Moon
11 Jung Kim^{2,*}

12

13

14

15 ¹Department of Laboratory Medicine, College of Medicine, Kangwon National University,
16 Chuncheon, Korea

17

18 ²Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of
19 Medicine, Goyang, Korea

20

21 ³Research Administration Team, Institute of Clinical Medicine, Myongji Hospital, Hanyang
22 University College of Medicine, Goyang, Korea

23

24 ⁴Department of General Affairs, Korean Association of Otorhinolaryngologists, Seoul, Korea

25

26

27 *Corresponding author

28 E-mail: kimmunj@gmail.com

29

30 **Abstract**

31 Rapid and accurate detection of the severe acute respiratory syndrome coronavirus 2
32 (SARS-CoV-2) is essential for the successful control of the current global COVID-19 pandemic.
33 The real-time reverse transcription polymerase chain reaction (Real-time RT-PCR) is the most
34 widely used detection technique. This research describes the development of two novel
35 multiplex real-time RT-PCR kits, *AccuPower*[®] COVID-19 Multiplex Real-Time RT-PCR Kit
36 (NCVM) specifically designed for use with the *ExiStation*[™]48 system (comprised of
37 *ExiPrep*[™]48 Dx and *Exicycler*[™]96 by BIONEER, Korea) for sample RNA extraction and
38 PCR detection, and *AccuPower*[®] SARS-CoV-2 Multiplex Real-Time RT-PCR Kit (SCVM)
39 designed to be compatible with manufacturers' on-market PCR instruments. The limit of
40 detection (LoD) of NCVM was 120 copies/μL and the LoD of the SCVM was 2 copies/mL for
41 both the gene and the SARS-CoV-2 gene (N gene and RdRp gene). The *AccuPower*[®] kits
42 demonstrated high precision with no cross reactivity to other respiratory-related
43 microorganisms. The clinical performance of *AccuPower*[®] kits was evaluated using the
44 following clinical samples: sputum and nasopharyngeal/oropharyngeal swab (NPS/OPS)
45 samples. Overall agreement of the *AccuPower*[®] kits with a Food and Drug Administration
46 (FDA) approved emergency use authorized commercial kit (STANDARD[™] M nCoV Real-
47 Time Detection kit, SD BIOSENSOR, Korea) was above 95% (Cohen's kappa coefficient \geq
48 0.95), with a sensitivity of over 95%. The NPS/OPS specimen pooling experiment was
49 conducted to verify the usability of *AccuPower*[®] kits on pooled samples and the results showed
50 greater than 90% agreement with individual NPS/OPS samples. The clinical performance of
51 *AccuPower*[®] kits with saliva samples was also compared with NPS/OPS samples and
52 demonstrated over 95% agreement (Cohen's kappa coefficient > 0.95). This study shows the
53 BIONEER NCVM and SCVM assays are comparable with the current standard confirmation
54 assay and are suitable for effective clinical management and control of SARS-CoV-2.

55 Keywords: SARS-CoV-2, COVID-19, Real-Time RT-PCR, Multiplex PCR Kits, diagnostic

56

57 **Introduction**

58 Coronavirus disease 2019 (COVID-19) was first detected in Wuhan, China in 2019,
59 and its outbreak has spread to other countries which led to a global pandemic (1). The virus
60 that causes COVID-19 was named severe acute respiratory syndrome coronavirus 2 (SARS-
61 CoV-2), which is the seventh known coronavirus that can infect humans (2). According to
62 World Health Organization (WHO), as of June 30, 2021, approximately 181 million people
63 were confirmed with SARS-CoV-2 infection, and 3.9 million were dead world-wide.
64 (<https://covid19.who.int/>).

65 The key strategy for controlling outbreaks of COVID-19 is early and accurate
66 detection of SARS-CoV-2 in the community. Real-time reverse transcription polymerase chain
67 reaction (Real-time RT-PCR) a gold standard method in the detection of various viral diseases,
68 is also the most reliable and accessible method for the diagnosis of SARS-CoV-2 infection (3).
69 SARS-CoV-2 is a positive-sense single-strand RNA virus that consists of RNA-dependent
70 RNA polymerase (RdRp) in an ORF1ab (4), envelope, nucleocapsid, spike, and membrane
71 protein. The genes of these regions have been chosen as the target for the detection of SARS-
72 CoV-2 (5). RNA viruses have a high tendency for multiple mutations. The mutations in the
73 RNA sequence can decrease the detection ratio of the primers and probes, which may lead to
74 the increased false-negative rates. Thus, the primers and probes in this study are designed to
75 target multiple conserved regions to minimize the false negatives caused by mutations.

76 Two novel multiplex Real-Time RT-PCR kits, *AccuPower*[®] COVID-19 Multiplex

77 Real-Time RT-PCR Kit (Cat No. NCVM-1111, BIONEER, Korea) and *AccuPower*[®] SARS-
78 CoV-2 Multiplex Real-Time RT-PCR Kit (Cat No. SCVM-2112, BIONEER, Korea), were used
79 in this study to detect the three viral genes of SARS-CoV-2 (RdRp gene, E gene, and N gene).
80 The NCVM is a premixed product that is specifically designed to be used with the
81 *ExiStation*TM48 system (*ExiPrep*TM48 Dx & *Exicycler*TM96, BIONEER, Korea), in which the
82 test is processed automatically from RNA extraction to PCR detection and confirmation. The
83 SCVM has been developed for use with various other manufacturers' PCR instruments. The
84 limit of detection (LoD), cross-reactivity, and precision of the *AccuPower*[®] kits (SCVM and
85 NCVM) were evaluated with SARS-CoV-2 positive materials as well as commonly used
86 human clinical samples (sputum samples and nasopharyngeal swab (NPS)/oropharyngeal swab
87 (OPS) samples). In addition, the clinical performance of the *AccuPower*[®] kits was verified for
88 use in the NPS/OPS specimen pooling test and with saliva samples.

89

90 **Materials and Methods**

91 **Primers and Probe Design**

92 Primers and probes were designed to detect SARS-CoV-2 RNA according to two
93 guidelines, the WHO Interim guideline and the KDCA (Korea Disease Control and Prevention
94 Agency) guideline. The primers and probes target three different genes of SARS-CoV-2 (RdRP
95 gene, N gene, and E gene). *In silico* analysis for inclusivity was conducted by comparing
96 primers and probes for an alignment with all COVID-19 sequences (n=3037) in the GISAID
97 database as of April 9th, 2020. The MUSCLE alignment was generated by multiple sequence
98 alignment and viewed in Jalview. *In silico* analyses were performed against the updated

99 standard database (n= 1,060,413 May 31, 2021) of the National Center for Biotechnology
100 Information to confirm the current coverage of primers and probes. The coverage change of
101 primers and probes was not significant. The target genes and coverage of each primer or probe
102 are stated in Table 1.

103

104 **Table 1. The target genes and coverage of primer and probe of the *AccuPower*[®] kits**

Target Gene	Oligomer	Coverage (%)	Max. Coverage (%)	Current Coverage (%)
E gene 1	Forward primer	99.97%		
	Reverse primer	99.96%	100%	99.94%
	Probe	99.96%		
E gene2	Forward primer	99.99%		
	Reverse Primer1	99.93%		
	Reverse Primer2	100%	100%	99.94%
	Probe	100%		
RdRp gene 2-2	Forward primer	99.99%		
	Reverse primer	99.98%	100%	99.89%
	Probe	99.98%		
N gene	Forward primer	96.67%		
	Reverse primer	99.40%	99.97%	95.06%
	Probe	99.89%		

105

106 *AccuPower*[®] Kits

107 *AccuPower*[®] kits contain specific primer, specific dual-labeled fluorogenic (TaqMan[®])
108 probe, DNA polymerase, reverse transcriptase, dNTPs, and stabilizer. Primers and fluorescent
109 probes attach specific sequences, which distinctively appear in the SARS-CoV-2 gene.

110 TaqMan[®] probe contains the fluorescence in the 5' end and the quencher in the 3' end so the
111 fluorescence is not released in the usual state. The fluorescence signal is emitted as the 5'-3'
112 exonuclease in DNA polymerase detaches from the probe, while the fluorescence and the
113 quencher detach during PCR.

114 The RNA presence can be detected by fluorescence signals. The NCVM is a freeze-
115 dried premixed product for use only with the *ExiStation*[™]48 system (*ExiPrep*[™]48 Dx &
116 *Exicycler*[™]96). The SCVM is a master-mix product, which can be used with various PCR
117 instruments. PCR reaction of *AccuPower*[®] kits was conducted according to each manufacturer's
118 protocol.

119

120 **Analytical Performance Evaluation**

121 The LoD, cross-reactivity, and precision were analyzed using the AccuPlex[™] SARS-
122 CoV-2 Verification Panel (Virus-Like Particles, SeraCare, USA) for the NCVM, and SARS-
123 Related Coronavirus 2 (Isolate USA-WA1/2020) for the SCVM. The RNA of the SARS-CoV-
124 2 Panel was extracted after dilution with E gene and SARS-CoV-2 gene negative NPS/OPS or
125 sputum matrix, then the RT-PCR process was performed. RNA extraction and PCR were
126 performed on the *ExiStation*[™] 48 system. RNA extraction of the SARS-Related Coronavirus
127 2 was performed using the *ExiPrep*[™] 48 DX (BIONEER, Korea) after dilution of the NPS/OPS
128 or sputum matrix, following the manufacturer's instructions.

129

130 **Limit of Detection**

131 The LoD measurement was performed, following the CLSI guideline EP17-A2 (6).
132 The LoD for the E gene and the SARS-CoV-2 gene were determined by measuring the RNA
133 level in the AccuPlex™ SARS-CoV-2 Verification Panel (Virus-Like Particles, SeraCare, USA)
134 using the NCVM, and the SARS-Related Coronavirus 2 (Isolate USA-WA1/2020) using the
135 SCVM.

136 The AccuPlex™ SARS-CoV-2 Verification Panel were serially diluted to 6
137 concentration levels (240, 200, 160, 120, 80, 40 copies/mL) for the NCVM testing. Each
138 dilution was tested in total 40 replicates, 20 replicates per lot, 2 lots. The SARS-Related
139 Coronavirus 2 (Isolate USA-WA1/2020) also were serially diluted to 6 concentration levels (6,
140 5, 4, 3, 2, 1 copies/μL) for the SCVM testing. Each dilution was tested in total 60 replicates,
141 20 replicates per lot, 3 lots. Both LoD tests were performed on the *Exicycler*™96 (BIONEER,
142 Korea) and determined using hit-rate analysis as the concentration at the lowest dilution that
143 can be detected with >95% probability.

144

145 **Cross-reactivity**

146 The cross-reactivity test was performed according to WHO EUL guidance (7) and
147 Food and Drug Administration (FDA) guideline (8). The specificity of *AccuPower*® kits for
148 SARS-CoV-2 detection was evaluated by *in silico* analysis followed by testing the SARS-CoV-
149 2 control with respiratory disease-related viruses and bacteria genes (concentration above
150 1.0×10^6 copies/mL). Altogether, 29 respiratory disease-related microorganisms were tested
151 using the NCVM and 38 were tested using the SCVM. The cross-reactivity test was performed
152 using the *Exicycler*™96.

153

154 **Precision**

155 The repeatability was tested according to the CLSI Guideline EP05-A3 (9) and EP15-
156 A3 (10). The repeatability of the *AccuPower*[®] kits performance was evaluated by intra-assay
157 and inter-assay variations at different concentrations of NPS/OPS, sputum, and saliva samples.

158

159 **Ethics Statement and Sample Collection**

160 Myongji Hospital Institutional Review Board (IRB) approved the use of surplus
161 clinical samples for the NPS/OPS specimen-pooling (IRB No.: MJH 2020-12-028) and
162 clinical performance evaluation (IRB No.: MJH 2020-12-029) tests. Kangwon National
163 University Hospital IRB approved the use of saliva and NPS/OPS samples for the clinical
164 performance testing of the *AccuPower*[®] kits (IRB No.: KNUH-2021-03-014), which were
165 either surplus samples or de-identified patient samples drawn after informed consent (Fig 1).
166 RNA in the NPS/OPS and sputum samples was extracted using the *ExiPrep*TM48 Viral
167 DNA/RNA Kit (BIONEER, Korea) with the *ExiPrep*TM48 Dx instrument and the RNA of
168 saliva samples was extracted using the *ExiPrep*TM48 Fast Viral RNA Kit (BIONEER, Korea)
169 with the *ExiPrep*TM48 Dx instrument. Previously, it was determined whether each sample was
170 SARS-CoV-2 positive or negative by the confirmation test.

171

172 **Fig 1. Summary of clinical specimens analyzed in this study.** NPS, Nasopharyngeal Swab;
173 OPS, Oropharyngeal Swab.

174

175 **Clinical Performance Evaluation Test**

176 The clinical performance of *AccuPower*[®] kits was evaluated by comparing the PCR
177 result of each *AccuPower*[®] kit to that of the confirmation test with confirmed positive or
178 negative samples. A total of 343 sputum samples and 343 NPS/OPS samples were collected for
179 clinical performance evaluation. The distribution of the Ct value of positive samples was
180 described in Supplementary S1 Fig. At least 30 % of positive samples had Ct values within the
181 cut-off Ct value - 10. The confirmation test was performed with the STANDARD[™] M nCoV
182 Real-Time Detection kit, the Q-Sens[®] COVID-19 Detection Kit V2 (CancerRop, Korea), or
183 the Allplex[™] 2019-nCoV Assay (Seegene, Korea) beforehand at the sample collection institute.
184 Presuming the result of the confirmation test was true, the clinical sensitivity and specificity of
185 *AccuPower*[®] kits were calculated. In addition, to validate the application of *AccuPower*[®] kits
186 as alternative diagnostic kits for SARS-CoV-2, the detection rate of confirmed positive and
187 negative samples was compared to samples tested using the *AccuPower*[®] kits and the reference
188 kit (STANDARD[™] M nCoV Real-Time Detection kit). STANDARD[™] M nCoV Real-Time
189 Detection kit is approved by the WHO and the FDA for SARS-CoV-2 detection for Emergency
190 Use Authorization (EUA) and officially approved the first kit by the Ministry of Food and Drug
191 Safety (MFDS), Korea. The RNA in samples was extracted using the *ExiPrep*[™]48 Viral
192 DNA/RNA Kit with the *ExiPrep*[™]48 Dx instrument. PCR reaction was conducted using the
193 *Exicycler*[™]96.

194

195 **Nasopharyngeal Swab and Oropharyngeal Swab Specimen**

196 **Pooling Test**

197 A 5-pool test on NPS/OPS samples was performed to evaluate the performance of the
198 *AccuPower*[®] kits on the pooled sample. A total of 180 samples (30 positive samples and 150
199 negative samples) were tested individually and in pools of 5 samples with the reference kit
200 (STANDARD[™] M nCoV Real-Time Detection kit) and the *AccuPower*[®] kits. At least 25 %
201 of the positive samples had Ct values within the cut-off Ct range of 2~3. The 30 positive
202 pooled samples and 30 negative pooled samples were prepared. Experimental positive pools
203 were created using 80 µL from one SARS-CoV-2 positive specimen mixed with 4 negative
204 patient specimens (80 µL each) for a total volume of 400 µL. Experimental negative pools
205 included 5 negative patient specimens (80 µL each). The RNA in pooled samples was
206 extracted using *ExiPrep*[™]48 Viral DNA/RNA Kit with the *ExiPrep*[™]48 Dx instrument. PCR
207 reaction was conducted using the *Exicycler*[™]96.

208 The *AccuLoader*[™] (BIONEER, Korea) which was designed to automatically load
209 samples into a reaction well was used to pool NPS/OPS specimens to reduce human error and
210 carry-over/cross-over contamination (Fig 2). A tablet PC connected to the *AccuLoader*[™]
211 controls the instrument, which consists of a barcode reader, a contamination shield cover, and
212 a contamination prevention filter. The user inputs the sample loading positions and volumes
213 into the PC, then, and after reading the 1D barcode attached to each sample collection tube, the
214 instrument directs the well-plate to automatically move to the proper position which prevents
215 sample from being loaded in the wrong well. A contamination shield cover protects other wells
216 from splashes that may occur during sample loading and a contamination prevention filter
217 minimizes cross-contamination from tip contact. For the pooling test, users input the number
218 of samples and the pooled volume, and the software calculated the required volume of each

219 sample in the pool.

220

221 **Fig 2. NPS/OPS specimens pooling with the *AccuLoader*TM.** *AccuLoader*TM recognizes the
222 information of each sample by scanning the barcode on a sample tube, then guides the user to
223 dispense samples in the correct well.

224

225 **Clinical Performance of *AccuPower*[®] kits with Saliva Samples**

226 The clinical performance of *AccuPower*[®] kits with saliva samples was evaluated by
227 analyzing the correlation between the PCR results of saliva samples and that of NPS/OPS
228 samples. Saliva and NPS/OPS samples were collected in pairs from each patient. Patients were
229 in a variety of stages in COVID-19 from asymptomatic period to 22 days after symptom onset.
230 Altogether, 47 positive and 40 negative saliva and NPS/OPS paired samples were collected and
231 stored. The RNA was extracted using the *ExiPrep*TM48 Fast Viral RNA Kit with the *ExiPrep*TM48
232 DX instrument. PCR reaction was conducted using the *Exicycler*TM96.

233 Saliva samples were collected and stored using the Saliva Collection Kit (BIONEER,
234 Korea), which was developed to collect, transport, and preserve saliva specimens for extraction
235 of human genomic DNA, bacterial genomic DNA, and viral DNA/RNA for disease detection.
236 Collection kits were gently inverted 5 times after saliva collection to properly mix the saliva
237 and the preservation buffer.

238

239 **Statistical Analysis**

240 Statistical analyses were conducted with R Studio 1.3.1093. In addition, the 2x2
241 contingency-table method was used for analyzing sensitivity, specificity, agreement, and
242 Cohen's kappa coefficient. Kendall's W test was used for analyzing the correlation between
243 PCR results in saliva samples and those in NPS/OPS samples.

244

245 Results

246 Limit of Detection

247 The LoD of NCVM was 120 copies/mL for the E gene (hit rate = 95%) and 120
 248 copies/mL for the SARS-CoV-2 gene (hit rate = 95%) using the *ExiStation*TM48 System
 249 (*ExiPrep*TM48 Dx & *Exicycler*TM96). The LoD of SCVM was 2 copies/ μ L for the E gene (hit
 250 rate = 95%), 2 copies/ μ L for the SARS-CoV-2 gene (hit rate = 95%) using the *ExiCycler*TM96.
 251 (Table 2).

253 **Table 2. Characteristic and PCR condition for LoD test of the *AccuPower*[®] kits**

RT-PCR kit	Mix type	RNA extraction equipment	PCR equipment	Target genes	Limit of detection
<i>AccuPower</i> [®] COVID-19 Multiplex Real-Time RT-PCR Kit	Premix	<i>Existation</i> TM 48	<i>Existation</i> TM 48	E gene *SARS-CoV-2 gene	E gene: 120 copies/mL SARS-CoV-2 gene: 120 copies/mL
<i>AccuPower</i> [®] SARS-CoV-2 Multiplex Real-Time RT-PCR Kit	Master mix	<i>Exiprep</i> TM 48 DX	<i>Exicycler</i> TM 96	E gene *SARS-CoV-2 gene	E gene: 2 copies/ μ L SARS-CoV-2 gene: 2 copies/ μ L

254 *SARS-CoV-2 gene: RdRp gene and N gene

255

256 Cross-reactivity

257 Based on *in silico* analysis, the designed primer and probe sequences were not
 258 expected to have a significant PCR amplification by other respiratory disease-related
 259 microorganisms, and this proved to be correct. The *AccuPower*[®] kits showed no positivity to

260 respiratory disease-related viruses or bacteria except E gene positivity on NATrol Coronavirus-
261 SARS Stock (qualitative, NATSARS-ST / 2003-00592). Since NATrol Coronavirus-SARS
262 Stock originally contains the E gene, it was concluded that none of the *AccuPower*[®] kits
263 exhibited cross-reactions with other respiratory viruses or bacteria (Table 3).

264

265 **Table 3. List of pathogens tested for cross-reactivity**

No	Organism	No	Organism
1	Human Influenza virus A H3N2	20	Parainfluenza virus 4a
2	Human Influenza virus A H1N1	21	Chlamydia pneumoniae
3	Human Influenza virus B (Texas/6/11) (Victoria)	22	Haemophilus influenzae
4	Human Coronavirus 229E	23	Legionella pneumophila
5	Human Coronavirus NL63	24	Streptococcus pneumoniae
6	Human Coronavirus OC43	25	Streptococcus pyogenes
7	Human Respiratory syncytial virus A	26	Bordetella pertussis
8	Human Respiratory syncytial virus B	27	Mycoplasma pneumoniae
9	Human Rhinovirus 14 (type B)	28	Pooled Human nasal wash - to represent diverse microbial flora in the human respiratory tract
10	Human Metapneumovirus(hMPV)	29	NATrol Coronavirus-SARS Stock (qualitative) (NATSARS-ST/ 2003-00592)
11	Human Adenovirus type 3 (type B)	30	Enterovirus 70
12	Enterovirus 71	31	Coxsackievirus B5
13	Mycobacterium tuberculosis H37Rv	32	Echovirus 25
14	MERS-CoV	33	Human Parachovirus 3
15	Human coronavirus HKU1 (HCOV-HKU1)	34	Mycobacterium fortuitum
16	Adenovirus(71)	35	Mycobacterium intracell
17	Parainfluenza virus 1	36	Mycobacterium gordonae

18	Parainfluenza virus 2	37	Mycobacterium chelonae
19	Parainfluenza virus 3	38	Pneumocystis jirovecii(PJP)

266 Cross reactivity was evaluated using both *in silico* analysis and by PCR test. Cross reactivity
267 of NCVM was tested with 29 pathogens (No.1 - 29). Cross-reactivity of SVCVM was tested with
268 38 pathogens (No.1 - 38).

269

270 Precision

271 The repeatability of the *AccuPower*[®] kits was analyzed by comparing Ct values of the
272 PCR result within runs, between runs, and between days in each matrix at each concentration.
273 The standard deviation (SD) of Ct values in each condition was calculated. The SD result
274 indicates no significant difference in Ct values for positive controls within-run, between-run,
275 between-day, and total precision. (S1 Table).

276

277 Clinical Performance Evaluation Test

278 The clinical performance of the NCVM was evaluated by comparing it to the
279 confirmation test. For sputum samples, the clinical sensitivity of NCVM was 97.50% (95% CI:
280 93.72% - 99.31%) and the clinical specificity was 98.36% (95% CI: 95.28% - 99.66%). For
281 NPS/OPS samples, the clinical sensitivity the NCVM was 100.00% (95% CI: 97.72% -
282 100.00%) and the clinical specificity was 98.91% (95% CI: 96.11% - 99.87%) (Table 4).

283

284 **Table 4. Clinical sensitivity and specificity evaluation results for the *AccuPower*[®] kits in**

285 **Sputum or NPS/OPS specimens.**

RT-PCR Kit	Specimen type	N	Sensitivity (%)	95% CI(%)	Specificity (%)	95% CI (%)
<i>AccuPower</i> [®]	Sputum	343	97.50	93.72 - 99.31	98.36	95.28 - 99.66
COVID-19 Multiplex Real-Time RT- PCR Kit	NPS/OPS	343	100.00	97.72 - 100.00	98.91	96.11 - 99.87
<i>AccuPower</i> [®]	Sputum	343	98.75	95.56 - 99.85	99.45	96.99 - 99.99
SARS-CoV-2 Multiplex Real- Time RT-PCR Kit	NPS/OPS	343	98.75	95.56 - 99.85	98.91	96.11 - 99.87

286

287 The correlation of the PCR result of the NCVM and that of the reference kit was also
 288 evaluated. For sputum samples, the positive percentage agreement was 96.27% (95% CI: 92.07%
 289 - 98.62%), the negative percentage agreement was 98.90% (95% CI: 96.07% - 99.87%), the
 290 total percentage agreement was 97.38% (95% CI: 95.08% - 98.79%), and the Cohen's kappa
 291 coefficient was 0.95. For NPS/OPS samples, the positive percentage agreement was 98.14%
 292 (95% CI: 94.65% - 99.61%), the negative percentage agreement was 98.90% (95% CI: 96.07%
 293 - 99.87%), the total percentage agreement was 98.25% (95% CI: 96.23% - 99.36%), and the
 294 Cohen's kappa coefficient was 0.97 (Table 5).

295

296 **Table 5. Clinical agreement evaluation results for the *AccuPower*[®] kits with**
 297 **STANDARD[™] M nCoV Real-Time Detection kit**

RT-PCR Kit	Specimen type	N	PPA(%)	95% CI(%)	NPA (%)	95% CI (%)	Cohen's kappa
------------	---------------	---	--------	-----------	---------	------------	---------------

<i>AccuPower</i> [®]	Sputum	343	96.27	92.07 - 98.62	98.90	96.07 - 99.87	0.95
COVID-19							
Multiplex Real-Time RT-PCR Kit	NPS/OPS	343	98.14	94.65 - 99.61	98.90	96.07 - 99.87	0.97
<i>AccuPower</i> [®]	Sputum	343	97.52	93.76 - 99.32	99.45	96.96 - 99.99	0.96
SARS-CoV-2							
Multiplex Real-Time RT-PCR Kit	NPS/OPS	343	98.14	94.65 - 99.61	99.45	96.96 - 99.99	0.97

298 PPA, Positive Percentage Agreement; NPA, Negative Percentage Agreement

299

300 The clinical performance of the SCVM was evaluated by comparing it to the
 301 confirmation test. For sputum samples, the clinical sensitivity of the SCVM was 98.75% (95%
 302 CI: 95.56% - 99.85%) and the clinical specificity was 99.45% (95% CI: 96.99% - 99.99%).
 303 For NPS/OPS samples, the clinical sensitivity of the SCVM was 98.75% (95% CI: 95.56% -
 304 99.85%) and the clinical specificity was 98.91% (95% CI: 96.11% - 99.87%) (Table 4).

305 The correlation between results of the SCVM and that of the reference kit was
 306 evaluated. For sputum samples, the positive percentage agreement was 97.52% (95% CI: 93.76%
 307 - 99.32%), the negative percentage agreement was 99.45% (95% CI: 96.96% - 99.99%), the
 308 total percentage agreement was 98.25% (95% CI: 96.23% - 99.36%), and the Cohen's kappa
 309 coefficient was 0.96. For NPS/OPS samples, the positive percentage agreement was 98.14%
 310 (95% CI: 94.65% - 99.61%), the negative percentage agreement was 99.45% (95% CI: 96.96%
 311 - 99.99%), the total percentage agreement was 98.54% (95% CI: 96.63% - 99.53%), and the
 312 Cohen's kappa coefficient was 0.97 (Table 5).

313 The correlation of Ct values in target genes among NCVM, SCVM, and
314 STANDARD™ M nCoV Real-Time Detection kit was analyzed by correlation analysis with the
315 plot in R studio and showed significant correlations with coefficient of determination (R^2) at
316 ≥ 0.97 (S2 Fig). An analysis of Ct values was also performed using the ANOVA test with master
317 mix kits (STANDARD™ M nCoV Real-Time Detection kit and SCVM). The ANOVA test
318 showed no significant difference between SCVM and STANDARD™ M nCoV Real-Time
319 Detection kit ($P > 0.05$) (S3 Fig).

320

321 **Nasopharyngeal Swab and Oropharyngeal Swab Specimen**

322 **Pooling Test**

323 Pooled samples were prepared as described above (S2 Table). Samples were then
324 tested individually using the *AccuPower*® kits and the reference kit. The test showed 100%
325 positive and negative agreement of the *AccuPower*® kits with the reference kit. The clinical
326 performance of the *AccuPower*® kits was also tested using in 5-pooled samples and evaluated
327 by comparing the PCR results from the *AccuPower*® kits to that of the reference kit. For NCVM,
328 the positive percentage agreement was 93.30% (95% CI: 77.93% - 99.18%) and the negative
329 percentage agreement was 100.00% (95% CI: 88.43% - 100.00%) with the reference test of
330 pooled samples.

331 The positive and negative agreement between pooled samples and individual samples
332 was also analyzed. For NCVM, the positive percentage agreement of pooled samples was 93.30%
333 (95% CI: 77.93% - 99.18%) and the negative percentage agreement was 100.00% (95% CI:
334 88.43% - 100.00%), compared to individual samples. The average Ct value of pooled samples

335 was 1.65 higher than the average Ct value of individual samples in the E gene and 1.90 higher
 336 in the SARS-CoV-2 gene (Fig 3.A). The degree of association between the Ct value of
 337 individual samples and the Ct value of pooled samples was analyzed by regression analysis
 338 and expressed as $y=0.887x+4.885$, $R^2=0.9700$ in the E gene and $y=0.983x+2.375$, $R^2=0.9955$
 339 in the SARS-CoV-2 gene (Fig 3.B).

340 For SCVM, the positive percentage agreement was of pooled samples 90.00% (95%
 341 CI: 73.47% -97.89%) and the negative percentage agreement was 100.00% (95% CI: 88.43%
 342 - 100.00%) compared to the reference test. In addition, the positive percentage agreement was
 343 90.00% (95% CI: 73.47% -97.89%) and the negative percentage agreement was 100.00% (95%
 344 CI: 88.43% - 100.00%) in pooled sample, compared to individual samples. The average Ct
 345 value of pooled samples was 0.94 higher than the average Ct value of individual samples in the
 346 E gene and 1.25 higher in the SARS-CoV-2 gene (Fig 3.A). The degree of association between
 347 the Ct value of individual samples and the Ct value of pooled samples was analyzed by
 348 regression analysis and expressed as $y=0.922x+2.841$, $R^2=0.9716$ in E gene and
 349 $y=1.017x+0.840$, $R^2=0.9976$ in SARS-CoV-2 gene (Fig 3.B). The results of the pooling tests
 350 are described in Table 6. The disagreement between the PCR results of pooled samples and
 351 those of individual samples has occurred only in samples with low concentration ($Ct > Cutoff$
 352 $Ct - 3$) of target genes (S3 Table).

353

354 **Table 6. The pooling test evaluation results for the *AccuPower*[®] kits**

Major discordance	Individual test (reference)			
	No.positive	No.negative	No.positive	No.negative
	Individual test (NCVM)		Pool test (NCVM)	

Positive	30	0	28	0
Negative	0	150	2	30
PPV (%)	100.00% (95% CI: 88.43% - 100.00%)		93.30% (95% CI: 77.93% - 99.18%)	
NPV (%)	100.00% (95% CI: 97.57% - 100.00%)		100.00% (95% CI: 88.43% - 100.00%)	
Accuracy (%)	100.00%		96.67%	
cohen's kappa (κ)	1.00		0.93	

355

Major discordance	Individual test (reference)			
	No.positive	No.negative	No.positive	No.negative
	Individual test (SCVM)		Pool test (SCVM)	
Positive	30	0	27	0
Negative	0	150	3	30
PPV (%)	100.00% (95% CI: 88.43% - 100.00%)		90.00% (95% CI: 73.47% - 97.89%)	
NPV (%)	100.00% (95% CI: 97.57% - 100.00%)		100.00% (95% CI: 88.43% - 100.00%)	
Accuracy (%)	100.00%		95.00%	
cohen's kappa (κ)	1.00		0.90	

356

357 **Fig 3. The comparison of Ct values in individual samples and pooled samples in NPS/OPS**
 358 **specimen pooling test (A) Ct values of individual and pooled samples in the *AccuPower*[®] kits.**
 359 **(B) The regression analysis with Ct values in individual samples and pooled samples in the**
 360 ***AccuPower*[®] kits.**

361

362 **Clinical Performance of *AccuPower*[®] kits with Saliva Samples**

363 The clinical performance of the *AccuPower*[®] kits for use with saliva samples was
 364 evaluated by comparing the PCR results in saliva samples to those in NPS/OPS samples. The

365 Ct values of each *AccuPower*[®] kit using both kinds of samples from diverse stages of COVID-
366 19 are shown in Fig 4.A.

367 The PCR results of each *AccuPower*[®] kit used with each type of sample were verified
368 by comparison to the confirmation test. The NCVM PCR results for NPS/OPS samples showed
369 97.87% (95% CI: 88.71% - 99.95%) positive agreement, the 100.00% (95% CI: 91.19% -
370 100.00%) negative agreement, and 98.85% (95% CI: 93.76% - 99.97%) total agreement with
371 a Cohen's kappa coefficient of 0.98, compared to the PCR results of the confirmation test for
372 NPS/OPS samples. The NCVM PCR results for saliva samples showed 100.00% (95% CI:
373 92.45% - 100.00%) positive agreement, 100.00% (95% CI: 91.19% - 100.00%) negative
374 agreement, and 100.00% (95% CI: 95.85% - 100.00%) total agreement with a Cohen's kappa
375 coefficient of 1.00, when compared to the PCR results of the confirmation test for NPS/OPS
376 samples. The comparison of the NCVM PCR results between NPS/OPS samples and saliva
377 samples showed that 100.00% (95% CI: 92.29% - 100.00%) positive agreement, 97.56% (95%
378 CI: 87.14% - 99.94%) negative agreement, and 98.85% (95% CI: 93.76% - 99.97%) total
379 agreement with Cohen's kappa coefficient of 0.98.

380 The SCVM PCR results for NPS/OPS samples showed 97.87% (95% CI: 88.71% -
381 99.95%) positive agreement, 100.00% (95% CI: 91.19%- 100.00%) negative agreement, and
382 98.85% (95% CI: 93.76% - 99.97%) total agreement with a Cohen's kappa coefficient of 0.98,
383 compared to the PCR results of the confirmation test for NPS/OPS samples. The SCVM PCR
384 results for saliva samples showed 100.00% (95% CI: 92.45% - 100.00%) positive agreement,
385 100.00% (95% CI: 91.19% - 100.00%) negative agreement, and 100.00% (95% CI: 95.85% -
386 100.00%) total agreement with a Cohen's kappa coefficient of 1.00, compared to the PCR
387 results of the confirmation test for NPS/OPS samples. The comparison of the SCVM PCR

388 results between NPS/OPS samples and saliva samples showed 100.00% (95% CI: 92.29% -
 389 100.00%) positive agreement, 97.56% (95% CI: 87.14% - 99.94%) negative agreement, and
 390 98.85% (95% CI: 93.76% - 99.97%) total agreement, with a Cohen's kappa coefficient of 0.98.
 391 The results indicate the adequacy of the *AccuPower*[®] kits for the use with saliva samples (Table
 392 7).

393 The scatter plots of Ct values in paired NPS/OPS and saliva specimens were analyzed
 394 for each *AccuPower*[®] kit (Fig 4.B). The correlation of Ct values in paired NPS/OPS and saliva
 395 specimens showed no significant difference in the E gene and the SARS-CoV-2 gene. Kendall's
 396 W was over 0.5 in the E gene (W=0.639 for NCVM, 0.596 for SCVM) and the SARS-CoV-2
 397 gene (W=0.613 for NCVM, 0.589 for SCVM), showing a high degree of agreement. In addition,
 398 the association of Ct values in each type of sample with days from the onset of COVID-19 was
 399 examined (Fig 4.C). Up to 10 days from the onset of COVID-19, Ct values of saliva samples
 400 were lower than those of NPS/OPS samples. On the other hand, after 10 days from the onset
 401 of COVID-19, Ct values of NPS/OPS samples were lower than those of saliva samples.

402

403 **Table 7. Clinical performance evaluation results of the *AccuPower*[®] kits in saliva samples**

	Specimen	Positive	Negative	PPV (%) (95% CI %)	NPV (%) (95% CI %)	Cohen's kappa
SD Kit	NPS/OPS	47	40	-	-	-
NCVM	NPS/OPS	46	41	97.87 (88.71% - 99.95%)	100.00 (91.19% - 100.00%)	0.98
	Saliva	47	40	100.00 (92.45% - 100.00%)	100.00 (91.19% - 100.00%)	1.00
	NPS/OPS-saliva agreement				100.00	97.56

				(92.29% - 100.00%)	(87.14% - 99.94%)	
	NPS/OPS	46	41	97.87	100.00	0.98
				(88.71% - 99.95%)	(91.19% - 100.00%)	
SCVM	Saliva	47	40	100.00	100.00	1.00
				(92.45% - 100.00%)	(91.19% - 100.00%)	
	NPS/OPS-saliva agreement			100.00	97.56	0.98
				(92.29% - 100.00%)	(87.14% - 99.94%)	

404 PPA, Positive Percentage Agreement; NPA, Negative Percentage Agreement

405

406 **Fig 4. Clinical performance of the *AccuPower*[®] kits in saliva and NPS/OPS samples (A)**

407 Ct values of saliva and NPS/OPS samples from patients in various stages of COVID-19. (B)

408 Clinical performance comparison of the *AccuPower*[®] kits in saliva and NPS/OPS samples

409 shown in scatter plots. (C) Ct value comparison by boxplot among the NCVM, SCVM, and

410 STANDARD[™] M nCoV Real-Time Detection kit. ASX, Asymptomatic.

411

412 Discussion

413 The COVID-19 pandemic became the catalyst for the development of more rapid and

414 accurate detection methods for SARS-CoV-2 to better support the clinicians and front-line

415 healthcare professionals (11). While effective vaccines have been developed, the availability

416 of high-quality diagnostic methods remains essential (12). Many studies continue to target a

417 more efficient, reliable, and sensitive detection method for SARS-CoV-2. On the other hand,

418 multiplex RT-PCR viral RNA detection assays have been developed for fast and reliable SARS-

419 CoV-2 detection (13-16).

420 The analytical performance of two *AccuPower*[®] kits (NCVM as the premix type and
421 SCVM as the master mix type) was evaluated. The NCVM was designed to be used on a closed
422 system (*ExiStation*[™]48 system) to provide full automation and contamination-free and error-
423 free results. The LoD of the NCVM was 120 copies/mL for the E gene and the SARS-CoV-2
424 gene as determined by the *ExiStation*[™]48 system. On the other hand, the SCVM was designed
425 to be used on an open system compatible with other manufacturers' PCR instruments. The LoD
426 of the SCVM was 2 copies/ul for the E gene and the SARS-CoV-2 gene as determined by the
427 *Exicycler*[™] 96. In addition, The LoD was determined by multiple alternative PCR instruments
428 (CFX96[™] Real-Time PCR Detection System (Bio-rad, USA), Applied Biosystems 7500 Fast
429 Real-time PCR Instrument system (Thermo Fisher Scientific, USA), QuantStudio[™]5 Real-
430 Time PCR Instrument (Thermo Fisher Scientific), *Exicycler*[™]384 (BIONEER, Korea),
431 *Exicycler*[™]96 Fast (BIONEER, Korea)) and the results demonstrated comparable performance
432 (S4 Table). Cross-reactivity was tested with 29 respiratory disease-related viruses and bacteria
433 genes were performed for the NCVM, and with 38 for the SCVM, respectively. The results
434 showed that there was no detectable cross-reactivity in *AccuPower*[®] kits, Precision of the two
435 *AccuPower*[®] kits was evaluated and the results showed high within-run, between-run, between-
436 day, and total precision.

437 This study provides the data to support the usability of the *AccuPower*[®] kits for the
438 detection of SARS-CoV-2 RNA in sputum and NPS/OPS clinical samples as evidenced by
439 equivalency with the confirmation test, which was performed in the collection institute
440 beforehand, and with the reference kit (STANDARD[™] M nCoV Real-Time Detection kit).
441 Specifically, the results of the *AccuPower*[®] kits were validated with over 95% agreement with
442 both the confirmation test and the reference kit. On the other hand, the NPS/OPS specimen

443 pooling test showed the PCR result of the pooled samples of 5 individuals had over 90%
444 agreement with the individual samples by the *AccuPower*[®] kits. The PCR results of the
445 *AccuPower*[®] kits in saliva samples showed over 95% positive and negative agreement with
446 those in the NPS/OPS samples, confirming the usability of the *AccuPower*[®] kits for the saliva
447 samples as well. In addition, the correlation between Ct values and days from the onset of
448 COVID-19 in both NPS/OPS and saliva samples indicates the saliva samples are more suitable
449 for detection up to 10 days from the onset of COVID-19 and the NPS/OPS samples are more
450 suitable for detection after 10 days from the onset of COVID-19 for SARS-CoV-2 detection.
451 This result is consistent with the previous studies on the COVID-19 saliva samples (17). In
452 brief, the analytical and clinical performance of the *AccuPower*[®] kits showed they are as
453 effective in the SARS-CoV-2 detection kit as the current standard confirmation test including
454 the reference kit.

455 A previous study presented the LoD of *AccuPower*[®] kits without the appropriate
456 number of replications, using quantified specimens RNA for the test (18). On the contrary, in
457 this study, The LoD test was performed with 20 replicates, which is recommended in the CLSI
458 guideline, using SARS-CoV-2 verification panel and SARS-Related Coronavirus 2. In addition,
459 the clinical performance of each *AccuPower*[®] kit was tested with clinical samples of various Ct
460 and verified by comparing them to the performance of STANDARD[™] M nCoV Real-Time
461 Detection kit, which obtained WHO and FDA approval for emergency use and MFDS official
462 approval and showed high agreements (>95%). STANDARD[™] M nCoV Real-Time Detection
463 kit showed higher clinical sensitivity with Allplex[™] 2019-nCoV Assay in a comparison study
464 (15). Also, the clinical performance evaluation of *AccuPower*[®] kits, assuming the result of
465 Allplex[™] 2019-nCoV Assay, which was one type of test in the confirmation test, as true,

466 indicated high sensitivity and specificity (>95%) (S5 Table). Thus, it may be suggested that
467 *AccuPower*[®] kits have equivalent clinical sensitivity with Allplex™ 2019-nCoV Assay.

468 In conclusion, this study describes the successful development of two multiplex real-
469 time RT-PCR methods, NCVN and SCVN, for the diagnosis of SARS-CoV-2. Simultaneous
470 targeting of three viral genes (RdRP, N, and E) by the *AccuPower*[®] kits provides an accurate,
471 reliable, and easy-to-use SARS-CoV-2 detection test. The *AccuPower*[®] kits demonstrate the
472 analytical performance characteristics expected of a valid diagnostic assay. The clinical
473 performance of the *AccuPower*[®] kits was comparable to the gold standard confirmation test,
474 including the reference kit. In addition, the specimen pooling test with n=5 showed the ability
475 of the *AccuPower*[®] to process high volume samples cost-effectively for use as a surveillance
476 tool. The clinical performance test of *AccuPower*[®] kits in saliva samples demonstrated the
477 usability of the *AccuPower*[®] kits with saliva samples and the saliva samples being more
478 adequate than NPS/OPS samples for early detection (before 10 days from the onset of symptom)
479 of COVID-19. The *AccuPower*[®] assay can be used for the fast and dependable detection of the
480 SARS-CoV-2 virus.

481

482 **Acknowledgments**

483 This research was supported by a grant of the Korea Health Technology R&D Project
484 through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of
485 Health & Welfare, Republic of Korea (grant number: HI20C2557).

486

487 **References**

- 488 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
489 associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
- 490 2. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of
491 SARS-CoV-2. *Nat Med*. 2020;26(4):450-2.
- 492 3. Kudo E, Israelow B, Vogels CBF, Lu P, Wyllie AL, Tokuyama M, et al. Detection of
493 SARS-CoV-2 RNA by multiplex RT-qPCR. *PLoS Biol*. 2020;18(10):e3000867.
- 494 4. van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den
495 Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *J*
496 *Clin Virol*. 2020;128:104412.
- 497 5. Liu R, Fu A, Deng Z, Li Y, Liu T. Promising methods for detection of novel
498 coronavirus SARS-CoV-2. *View*. 2020;1(1):e4.
- 499 6. CLSI. CLSI guideline EP17-A2. Evaluation of Detection Capability for Clinical
500 Laboratory Measurement Procedures. Clinical and Laboratory Standards Institute 2nd edition.
501 2012; Wayne, PA.
- 502 7. CLSI. CLSI guideline EP07-A2. Interference Testing in Clinical Chemistry. Clinical
503 and Laboratory Standards Institute 2nd edition. 2005; Wayne, PA.
- 504 8. FDA. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency
505 (Revised) - Immediately in Effect Guidance for Clinical Laboratories, Commercial
506 Manufacturers, and Food and Drug Administration Staff. 2020.
- 507 9. CLSI. CLSI guideline EP05-A3. Evaluating Quantitative Measurement Precision.
508 Clinical and Laboratory Standards Institute 3rd edition. 2014; Wayne, PA.
- 509 10. CLSI. CLSI guideline EP15-A3. User Verification of Precision and Estimation.

- 510 Clinical and Laboratory Standards Institute 3rd edition. 2014; Wayne, PA.
- 511 11. Mannonen L, Kallio-Kokko H, Loginov R, Jaaskelainen A, Jokela P, Antikainen J, et
512 al. Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection
513 of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA. *J Mol Diagn.*
514 2021;23(4):407-16.
- 515 12. Hacısuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine
516 Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine.* 2021.
- 517 13. Tombuloglu H, Sabit H, Al-Suhaimi E, Al Jindan R, Alkharsah KR. Development of
518 multiplex real-time RT-PCR assay for the detection of SARS-CoV-2. *PLoS One.*
519 2021;16(4):e0250942.
- 520 14. Zhen W, Berry GJ. Development of a New Multiplex Real-Time RT-PCR Assay for
521 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. *J Mol Diagn.*
522 2020;22(12):1367-72.
- 523 15. Hur KH, Park K, Lim Y, Jeong YS, Sung H, Kim MN. Evaluation of Four Commercial
524 Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved
525 by Emergency-Use-Authorization in Korea. *Front Med (Lausanne).* 2020;7:521.
- 526 16. Zhou Y, Pei F, Ji M, Wang L, Zhao H, Li H, et al. Sensitivity evaluation of 2019 novel
527 coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative. *PLoS*
528 *One.* 2020;15(11):e0241469.
- 529 17. Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, et al. Saliva is more
530 sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-
531 19 infection. *Scientific Reports.* 2021;11(1):3134.
- 532 18. Freire-Paspuel B, Garcia-Bereguain MA. Analytical and Clinical Evaluation of
533 "AccuPower SARS-CoV-2 Multiplex RT-PCR kit (Bioneer, South Korea)" and "Allplex 2019-

534 nCoV Assay (Seegene, South Korea)" for SARS-CoV-2 RT-PCR Diagnosis: Korean CDC EUA
535 as a Quality Control Proxy for Developing Countries. Front Cell Infect Microbiol.
536 2021;11:630552.

537

538 **Supporting information**

539 **S1 Fig. Ct value variation in collected clinical samples.** Nashpharyngeal and Oropharyngeal
540 swab specimens Ct distribution (Above). Sputum specimens Ct distribution (Below). *SD:
541 STANDARD™ M nCoV Real-Time Detection kit, Cutoff (Ct): 36 **CancerRop: Q-Sens®
542 COVID-19 Detection Kit V2, Cutoff (Ct): 40 ***Seegene: Allplex™ 2019-nCoV Assay,
543 Cutoff (Ct): 40

544 **S2 Fig. Correlation Analysis with plot among NCVM, SCVM, and STANDARD™ M**
545 **nCoV Real-Time Detection kit.** Ct values among assays (NCVM, SCVM and STANDARD™
546 M nCoV Real-Time Detection kit) showed high correlation with a Pearson R² correlation
547 coefficient ≥ 0.97 .

548 **S3 Fig. Comparison between SCVM and STANDARD™ M nCoV Real-Time Detection**
549 **kit.** Results of ANOVA test showed no significant difference between SCVM and
550 STANDARD™ M nCoV Real-Time Detection kit ($p > 0.05$).

551 **S1 Table. Precision evaluation results for the AccuPower® kits.** Precision evaluation results
552 of AccuPower® COVID-19 Multiplex Real-Time RT-PCR Kit and AccuPower® SARS-CoV-
553 2 Multiplex Real-Time RT-PCR Kit.


554 **S2 Table. Individual samples and pooled samples in swab specimen pooling test.**


555 **S3 Table. The agreement between individual samples and pooled samples in the**
556 ***AccuPower*[®] kits.**

557 **S4 Table. Limit of detection of SCVM in various PCR instruments.**

558 **S5 Table. Clinical sensitivity and specificity evaluation results for the *AccuPower*[®] kits in**

559 **Sputum or NPS/OPS specimens, compared to Allplex[™] 2019-nCoV Assay.**





AccuLoader™

Multi-Well Sample Loader

Recognizing samples information and dispensing samples using AccuLoader™

Step 1.




1. Run the AccuLoader App

Step 2.







2. Set up the app according to the condition you want to be dispense
3. After setting, touch the start button

Step 3.



3. Recongnition of sample information through barcode scanner
4. Dispense sample into wells guided by AccuLoader

A**B**